View Older Stories View More Recent Stories
-
Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller
-
Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update
-
Form SC 13D/A Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Selux Diagnostics Announces Additional $50 Million in Series C Funding
-
Form SC 13G Vera Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Somatus Raises $325M to Deliver Proven Value-Based Kidney Care Model to More Americans with Kidney Disease
-
Plexium Announces $102M Financing To Advance Pipeline Of Targeted Protein Degradation Therapies And Technology Platform
-
Form SC 13G/A scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-phase Research to the Clinic
-
Form SC 13G/A Kinnate Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ChemoCentryx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ImmunoGen, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Atea Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Dec 31
-
Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Seres Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ZOGENIX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A CONCERT PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A 5:01 Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Silverback Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Cyteir Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Viridian Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A KalVista Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A MACROGENICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A OTONOMY, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Edgewise Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Larimar Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Tango Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A BCLS Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Travere Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Verona Pharma plc Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Orchard Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Pyxis Oncology, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A PhaseBio Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Milestone Pharmaceutical Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Olema Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Dyne Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A CytomX Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Astria Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Frazier Lifesciences Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Nautilus Biotechnology, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Akouos, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A NOVAVAX INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A GERON CORP Filed by: RA CAPITAL MANAGEMENT, L.P.

